Publication:
Surgically treated pelvic liposarcoma and leiomyosarcoma: the effect of tumor size on cancer-specific survival

dc.contributor.coauthorBaudo, Andrea
dc.contributor.coauthorPiccinelli, Mattia Luca
dc.contributor.coauthorIncesu, Reha-Baris
dc.contributor.coauthorMorra, Simone
dc.contributor.coauthorScheipner, Lukas
dc.contributor.coauthorBarletta, Francesco
dc.contributor.coauthorTappero, Stefano
dc.contributor.coauthorGarcia, Cristina Cano
dc.contributor.coauthorAssad, Anis
dc.contributor.coauthorTian, Zhe
dc.contributor.coauthorAcquati, Pietro
dc.contributor.coauthorde Cobelli, Ottavio
dc.contributor.coauthorLongo, Nicola
dc.contributor.coauthorBriganti, Alberto
dc.contributor.coauthorTerrone, Carlo
dc.contributor.coauthorChun, Felix K.H.
dc.contributor.coauthorAhyai, Sascha
dc.contributor.coauthorSaad, Fred
dc.contributor.coauthorShariat, Shahrokh F.
dc.contributor.coauthorCarmignani, Luca
dc.contributor.coauthorKarakiewicz, Pierre I.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorTilki, Derya
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-12-29T09:39:52Z
dc.date.issued2024
dc.description.abstractIntroduction: In soft tissue pelvic liposarcoma and leiomyosarcoma, it is unknown whether a specific tumor size cut-off may help to better predict prognosis, defined as cancer-specific survival (CSS). We tested whether different tumor size cut-offs, could improve CSS prediction. Materials and methods: Surgically treated non-metastatic soft tissue pelvic sarcoma patients were identified (Surveillance, Epidemiology, and End Results 2004–2019). Kaplan-Meier plots, univariable and multivariable Cox-regression models and receiver operating characteristic-derived area under the curve (AUC) estimates were used. Results: Overall, 672 (65 %) liposarcoma (median tumor size 11 cm, interquartile range [IQR] 7–16) and 367 (35 %) leiomyosarcoma (median tumor size 8 cm, IQR 5–12) patients were identified. The p-value derived ideal tumor size cut-off was 17.1 cm, in liposarcoma and 7.0 cm, in leiomyosarcoma. In liposarcoma, according to p-value derived cut-off, five-year CSS rates were 92 vs 83 % (≤17.1 vs > 17.1 cm). This cut-off represented an independent predictor of CSS and improved prognostic ability from 83.8 to 86.8 % (Δ = 3 %). Similarly, among previously established cut-offs (5 vs 10 vs 15 cm), also 15 cm represented an independent predictor of CSS and improved prognostic ability from 83.8 to 87.0 % (Δ = 3.2 %). In leiomyosarcoma, according to p-value derived cut-off, five-year CSS rates were 86 vs 55 % (≤7.0 vs > 7.0 cm). This cut-off represented an independent predictor of CSS and improved prognostic ability from 68.6 to 76.5 % (Δ = 7.9 %). Conclusions: In liposarcoma, the p-value derived tumor size cut-off was 17.1 cm vs 7.0 cm, in leiomyosarcoma. In both histologic subtypes, these cut-offs exhibited the optimal statistical characteristics (univariable, multivariable and AUC analyses). In liposarcoma, the 15 cm cut-off represented a valuable alternative. © 2024 Elsevier Ltd
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume54
dc.identifier.doi10.1016/j.suronc.2024.102074
dc.identifier.eissn1879-3320
dc.identifier.issn0960-7404
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85190298514
dc.identifier.urihttps://doi.org/10.1016/j.suronc.2024.102074
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23139
dc.identifier.wos1238878100001
dc.keywordsCancer-specific survival
dc.keywordsLeiomyosarcoma
dc.keywordsLiposarcoma
dc.keywordsPelvic soft tissue sarcoma
dc.keywordsTumor size cut-off
dc.language.isoeng
dc.publisherElsevier Ltd
dc.relation.ispartofSurgical Oncology-Oxford
dc.subjectOncology
dc.subjectSurgery
dc.titleSurgically treated pelvic liposarcoma and leiomyosarcoma: the effect of tumor size on cancer-specific survival
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorTilki, Derya
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files